Startseite

Aktien

Takeda Pharmaceutical Aktie

Nachrichten

Takeda Pharmaceutical Aktie

Aktie

ISIN: JP3463000004 WKN: 853849 SYM: TKD Land Flagge JP

Japan

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

24,590

EUR

+0,94 %

+0,230 EUR

Letzter Kurs 16:29:55 Tradegate

Takeda Pharmaceutical Aktie Aktie kaufen

Geldkurs

17:10:49

24,410

EUR

405 STK

Briefkurs

17:10:49

24,590

EUR

401 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Neueste Nachrichten

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies \| DelveInsight 03.12.25 · PR Newswire (engl.) · Bayer
Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due to Increasing Disease Awareness, Improved Diagnosis, and Expanding Therapeutic Options \| DelveInsight 02.12.25 · PR Newswire (engl.) · Takeda Pharmaceutical Aktie
HKSTP Crowns EPIC 2025 Winner: Champion of HKSTP EPIC 2025 NEU Battery Materials from Singapore Triumphs at Hong Kong's Flagship I&T Mega Event 07.11.25 · newsfile · Cathay Pacific Airways
HKSTP Manifesting 20 Latest BFSI Tech and Translation of R&D at Hong Kong FinTech Week x StartmeupHK Festival 2025 05.11.25 · newsfile · Cathay Pacific Airways
Kyowa Kirin International gibt Ernennung von Julie Dehaene-Puype zur Präsidentin für die Region bekannt 03.11.25 · Business Wire (dt.) · Kyowa Kirin
Takeda Pharmaceutical Stock: FY2025 Financial Forecast Update 30.10.25 · wO Newsflash · Takeda Pharmaceutical Aktie
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS) 30.10.25 · EQS Group AG · Takeda Pharmaceutical Aktie
TetraScience startet wissenschaftliches KI-Leuchtturmprogramm mit Takeda als Gründungspartner 24.10.25 · PR Newswire (dt.) · Microsoft
Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances \| DelveInsight 23.10.25 · PR Newswire (engl.) · Amgen
KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) \| DelveInsight 16.09.25 · PR Newswire (engl.) · Daiichi Sankyo
AGC Biologics-Werk in Seattle erreicht Meilensteinjahr mit behördlichen Zulassungen, Kundenzufriedenheit und ISO-Zertifizierungsprüfung ohne Beanstandungen 11.09.25 · Business Wire (dt.) · Heidelberger Druckmaschinen
Fokus Aktien mit extremen Handelsvolumen am Freitag, den 05.09.2025 05.09.25 · wO Chartvergleich · Ad Pepper Media International

1
2
…
3

Ad-hoc Nachrichten

Takeda Pharmaceutical Stock: FY2025 Financial Forecast Update 30.10.25 · wO Newsflash · Takeda Pharmaceutical Aktie
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS) 30.10.25 · EQS Group AG · Takeda Pharmaceutical Aktie

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) ... 288 Leser
Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due ... 148 Leser

Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) ... 288 Leser
Narcolepsy Market is Projected to Grow at a CAGR of 5.6% During the Forecast Period (2025-2034) Due ... 148 Leser

Fokus Aktien mit extremen Handelsvolumen am Freitag, den 05.09.2025 600 Leser
LUPKYNIS Strengthens Market Position as Demand for Lupus Nephritis Treatment Grows \| DelveInsight 472 Leser
The World's 30 Best Places to Work for 2024 Revealed 340 Leser
Takeda Pharmaceutical Stock: FY2025 Financial Forecast Update 324 Leser
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) ... 288 Leser
Intravenous Immunoglobulin (IVIG) Market Forecast to Surge During the Forecast Period (2025-2034) ... 220 Leser
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in ... 220 Leser
Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) ... 188 Leser
AGC Biologics-Werk in Seattle erreicht Meilensteinjahr mit behördlichen Zulassungen, ... 188 Leser
TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy \| ... 180 Leser